Targeting TGF-β for treatment of osteogenesis imperfecta
A monoclonal antibody therapy that neutralizes TGF-β produced promising results in a Phase 1 clinical trial.
Read MoreA monoclonal antibody therapy that neutralizes TGF-β produced promising results in a Phase 1 clinical trial.
Read More